Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Liabilities and Shareholders Equity (2016 - 2025)

vTv Therapeutics' Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $99.5 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 130.5% year-over-year to $99.5 million; the TTM value through Dec 2025 reached $158.0 million, down 13.24%, while the annual FY2024 figure was $38.3 million, 247.3% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $99.5 million at vTv Therapeutics, up from $26.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $99.5 million in Q3 2025 and bottomed at $11.0 million in Q4 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $31.4 million (2021), against an average of $33.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 346.13% in 2021 before it tumbled 66.85% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $25.5 million in 2021, then skyrocketed by 30.48% to $33.2 million in 2022, then crashed by 66.85% to $11.0 million in 2023, then skyrocketed by 247.3% to $38.3 million in 2024, then skyrocketed by 160.01% to $99.5 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Liabilities and Shareholders Equity are $99.5 million (Q3 2025), $26.4 million (Q2 2025), and $32.0 million (Q1 2025).